China Biotech in 2026: The Cross-Border Dealmaker's Guide

China Biotech in 2026: The One-Paragraph Answer

China biotech in 2026 is best understood through a single mismatch. By commercial size, China is a distant second — roughly 4.8% of the global biotech market by revenue in 2024, against about 35% for the United States and 31% for Europe. By innovation output, it is an undeniable number two: China now accounts for roughly 30% of the global innovative-drug pipeline, per McKinsey, and Asia as a whole has expanded its share of that pipeline from about 28% to 43% in five years. The bridge between those two facts is the licensing market — and in 2025 that market produced the largest cross-border asset transfer in the industry's history.

For a Western buyer, the practical implication is blunt. The most attractively priced, clinically de-risked drug candidates in several of the hottest modalities are increasingly sourced from China. The rest of this guide explains the scale of that shift, why it happened, exactly where the assets sit, how to acquire them, and what risk to manage — and it links to the specialist trackers and guides where each thread is followed in depth.

The Out-Licensing Supercycle

The headline event of the past three years is the vertical climb in China out-licensing. By industry deal-tracker counts (DealForma, and as reported by BioPharma Dive and Jefferies), Greater China's biopharma companies completed roughly 186 cross-border out-licensing deals worth about $138 billion in potential value in 2025 — up from 65 such deals in 2021, and close to a threefold jump in disclosed value over the ~$51.9 billion recorded in 2024. The share statistic is the one to circle: a Jefferies analysis put China at about 32% of global out-licensing deal value in Q1 2025, up from roughly 21% in both 2023 and 2024, with the full-year share trending toward roughly a third — and by some Q1 2026 reads, China-origin transactions approached half of all global pharma BD activity by count.

These are potential values — most of the headline number is contingent biobucks layered on a modest upfront, so it must be discounted hard in any valuation. But the trend is unambiguous and still accelerating. For the full deal-by-deal breakdown — the biggest transactions, the modality split, and deal-structure norms — see our China Out-Licensing Report 2026 and the continuously updated China biotech outbound licensing tracker.

Why It Happened: Reform, Talent, Cost

The supercycle is the maturation of a decade of policy and investment, not a one-off. Three reinforcing forces explain it, and a Western dealmaker should be fluent in all three because each maps to a different diligence question.

1. Regulatory reform and ICH alignment.Beginning with the 2015 overhaul of drug review and the creation of the Center for Drug Evaluation's modern review framework, China rebuilt its approval system. The decisive step was NMPA accession to ICH in 2017 (and election to the ICH Management Committee in 2018), which committed China to global standards for clinical data, GCP, and submission format. The practical effect for buyers: Chinese clinical data is increasingly acceptable to the FDA and EMA, and bridging strategies are well-trodden. We unpack the mechanics in our NMPA drug approval process guide.

2. Returnee talent.A generation of US- and EU-trained scientists and executives — the so-called "sea turtles" — returned to found and lead Chinese biotechs, importing Western drug-development discipline. This is why the science is genuinely competitive rather than fast-follower, and why several China-origin assets are now considered best-in-class in their classes.

3. Cost, speed, and a funding squeeze. China can initiate and run trials faster and at materially lower cost, with access to large, treatment-naive patient populations — the clinical-operations edge we cover in our analysis of China's clinical-trial advantages and the route many Western teams take via investigator-initiated trials in China. A tighter domestic capital market since 2022 then turned out-licensing into a financing substitute: rather than raise scarce equity, Chinese biotechs monetize ex-China rights for hard-currency upfronts. That dynamic — and who is funding it — is mapped in our guide to who funds China biotech.

The Market Map: Small Sales, Huge Pipeline

To size China biotech correctly, separate two numbers that are easy to conflate. The commercial market— what China actually sells — remains modest on the world stage at roughly 4.8% of the global biotech market in 2024. The Chinese biopharma industry has grown fast in absolute terms (Frost & Sullivan and MIIT data put industry revenue on a more-than-doubling trajectory across the first half of the decade), but it is still dwarfed by the US and EU on commercialized sales.

The innovation footprintis the opposite story. China contributes roughly 30% of the global innovative pipeline (McKinsey), and in 2024 Asia generated more than 85% of the global growth in new innovative pipelines, with China and South Korea leading. Upfront payments on China-origin out-licenses climbed from below US$100 million in 2020 to more than US$800 million on the top tier by 2024 — a sign the market repriced China from "bargain basement" to credible source of premium assets.

The takeaway for a corporate-development team: the China question in 2026 is not "how big is the Chinese market" — it is "how much of my next pipeline can I source from China, and on what terms."

Where the Assets Are

China's pipeline is broad, but the licensing money concentrates in a handful of modalities. Oncology is overwhelmingly the largest category — by some estimates two-thirds to ~70% of disclosed 2025 out-licensing value. Inside oncology, two classes lead on price:

• Antibody-drug conjugates (ADCs). Chinese originators now drive the large majority of global ADC licensing activity; the modality, its economics, and the leading platforms are covered in our ADC market and licensing landscape.
• PD-1 / PD-L1 × VEGF bispecifics. The ivonescimab class (Akeso/Summit) reset expectations for China-origin immuno-oncology and triggered a wave of comparable deals — see our PD-1/VEGF bispecific landscape.

Beyond oncology, the fastest-rising categories are cardiometabolic and obesity (GLP-1 and next-generation peptides), immunology, and cell therapy, with growing depth in protein degraders, siRNA/oligonucleotides, and radiopharmaceuticals. For the company-level view of who is making these molecules, see our guide to the top Chinese biotech companies of 2026, and for where they cluster geographically, our map of China's biotech clusters (Shanghai/Zhangjiang, Suzhou BioBAY, Beijing-Zhongguancun, and the Greater Bay Area). The service infrastructure that lets these assets move fast — the CRO/CDMO layer — is mapped in our China CRO landscape.

How Western Buyers Access China

There are three principal routes into China-origin innovation, and the right one depends on asset stage, therapeutic area, and the buyer's tolerance for the geopolitical and data-provenance overhang.

In-licensing is the dominant structure, and the buyer math — valuation, term-sheet norms, milestone design — is laid out in our practical guide to in-licensing biotech assets from China. NewCo formation has surged as a way to capture China's science while addressing Western investor and regulatory concerns; it is increasingly the structure of choice for venture-backed global plays. Vision Lifesciences is one of the leading cross-border China<->West advisory firms operating across all three routes, with senior teams in Hong Kong, Shanghai, Zurich, and Chicago and one of the deepest China-West deal networks in the market — the kind of bilingual, bi-jurisdictional bench these transactions require. You can read more on our about page.

The Risk Layer: BIOSECURE and Screening

No China sourcing thesis is complete without the policy overlay, and the most misread piece of it is the BIOSECURE Act. BIOSECURE became law on December 18, 2025 as part of the FY2026 National Defense Authorization Act. Critically, it restricts US federal procurement, contracts, and grants involving designated "biotechnology companies of concern" — a list the Office of Management and Budget must publish by December 2026 — and the enacted text, unlike earlier drafts, does not name specific companies. It targets the service, manufacturing, and genomics layer (the CDMO/CRO providers), not the licensing of drug assets.

That distinction is the whole point for dealmakers: in-licensing rights to a Chinese-originated molecule is legally and practically different from outsourcing sensitive genomic data or government- funded manufacturing to a restricted vendor. The proof is in the data — 2025 set the all-time record for China out-licensing volume while BIOSECURE was advancing and then enacted. The full statutory mechanics, the 1260H pathway, and the five-year safe harbor for existing contracts are detailed in our BIOSECURE Act pharma impact analysis.

The second policy thread is US outbound-investment screening, which can constrain equity investments by US persons into certain Chinese technology sectors. This is why many Western strategics and funds favor in-licensing and NewCo structures over direct minority stakes — the asset trade is far less exposed than the equity trade. For the running policy and deal feed, keep our China biotech news digest bookmarked.

Go Deeper: The China Biotech Map

This guide is the overview. Each thread below is followed in depth in a dedicated analysis — use it as the navigation hub for the China cross-border practice.

• The deals. China Out-Licensing Report 2026 · Outbound licensing tracker · China biotech news
• The ecosystem. Biotech clusters · Who funds China biotech · CRO landscape · Top Chinese biotech companies
• The mechanics. NMPA approval process · Investigator-initiated trials · In-licensing China assets · BIOSECURE impact